Form 4: Ionis Pharmaceuticals Executive Exercises Stock Options and Sells Shares
SEC Form 4
Patrick R. O'Neil, EVP CLO & General Counsel at Ionis Pharmaceuticals, executed stock options and sold shares to cover tax obligations.
Summary
- Patrick R. O'Neil, an executive at Ionis Pharmaceuticals, acquired 19,690 shares of common stock through the vesting of restricted stock units on January 15, 2025.
- He then sold 7,360 shares on January 16, 2025, at an average price of $32.83 per share to cover tax obligations.
- O'Neil was also granted 22,000 performance restricted stock units (PRSUs) and 33,000 restricted stock units (RSUs) on January 15, 2025.
- The PRSUs have a three-year performance period and may vest up to 200% of the target number based on the company's total shareholder return compared to a peer group.
- The RSUs vest in four equal annual installments.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and stock transactions. There is no indication of any positive or negative sentiment, it is a routine filing.
Future Outlook
The performance restricted stock units (PRSUs) may vest at the end of a three-year performance period based on the company's total shareholder return compared to a peer group. The restricted stock units (RSUs) will vest in four equal annual installments.
Industry Context
This is a routine filing related to executive compensation and stock transactions, which is common in publicly traded companies. It reflects the standard practice of granting stock-based compensation to executives and the subsequent sale of shares to cover tax obligations.
Comparison to Industry Standards
- Stock-based compensation, including restricted stock units and performance-based units, is a common practice among publicly traded biotechnology and pharmaceutical companies like Ionis.
- Companies such as Alnylam Pharmaceuticals, Biogen, and Vertex Pharmaceuticals also utilize similar compensation structures to incentivize and retain key executives.
- The vesting schedules and performance metrics associated with these grants are generally aligned with industry standards, aiming to reward long-term value creation and shareholder returns.
- The sale of shares to cover tax obligations is a standard practice for executives receiving stock-based compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the sale of a small number of shares by an executive.
- The vesting of stock options and restricted stock units aligns executive interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Vesting of 19,690 shares, grant of 22,000 PRSUs and 33,000 RSUs. |
| 01/16/2025 | Sale of 7,360 shares at an average price of $32.83. |
| 01/17/2025 | Date of signature of the form. |
| 01/15/2028 | Expiration date of the Performance Restricted Stock Units. |
| 01/15/2026 | Expiration date of the Restricted Stock Units. |
Keywords
Ionis Pharmaceuticals, stock options, restricted stock units, insider trading, executive compensation, share sale, performance restricted stock units, tax obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.